Cardiology Letters 2021, 30(2):111-118
The effect of age and hypertension on activity of circulating matrix metalloproteinases (MMP-2 and MMP-9) in rats
- 1 Fyziologický ústav Lekárskej fakulty, Univerzita Komenského v Bratislave, Bratislava
- 2 Centrum experimentálnej medicíny, Ústav normálnej a patologickej fyziológie, Slovenská akadémia vied, Bratislava
- 3 Prírodovedecka fakulta, Univerzita Komenského v Bratislave, Bratislava
- 4 Ústav molekulárnej biomedicíny Lekárskej fakulty, Univerzita Komenského v Bratislave, Bratislava
- 5 Centrum experimentálnej medicíny, Ústav pre výskum srdca, Slovenská akadémia vied, Bratislava, Slovenská republika
Aims: Matrix metalloproteinases (MMPs) are important in the pathogenesis of many diseases, including cardiovascular. The aim of the proposed study was to monitor the activities of MMP-2 and MMP9 in spontaneously hypertensive rats (SHR) and their normotensive controls - Wistar-Kyoto rats (WKY) of different age categories.
Methods: Animals were divided into 6 groups, based on age (7, 20, and 52 weeks) and normo/hypertension: WKY-7, WKY-20, WKY-52, SHR-7, SHR-20, and SHR-52. Plasma activities of MMPs were determined by gelatin zymography. In addition, parameters of oxidative stress and antioxidant status, as well as NT-proBNP, as a marker of cardiac function and neurohumoral activation, were monitored.
Results: In young 7-week-old hypertensive animals (SHR-7) the activity of MMP-2 was higher compared with normotensive (WKY-7), whereas in older 52-week-old hypertensive animals (SHR-52) the activity of MMP-2 and MMP-9 was lower compared with normotensive controls (WKY-52). Regarding age-related changes, MMP-2 activities decreased with age and MMP-9 activities increased with age in both normotensive and hypertensive rats. The parameters of oxidative stress, antioxidant status, and NT-proBNP levels did not worsen with age.
Conclusion: Our results point to differences in the activation of different MMPs during aging. In addition, inhibition of MMP-2 could be therapeutically useful in developing hypertension. However, inhibition of MMP-2 and MMP-9 may not be desirable in fully developed and stabilized hypertension.
Keywords: gelatinases; hypertension; oxidative stress; spontaneously hypertensive rats
Published: February 1, 2021 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2010;1803:39-54. DOI: 10.1016/j.bbamcr.2009.09.015.
Go to original source... - Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. Journal of Enzyme Inhibition and Medicinal Chemistry. 2016; 31(sup1): 77-183. DOI: 10.3109/14756366.2016.1161620.
Go to original source... - Loffek S, Schilling O, Franzke CW. Biological role of matrix metalloproteinases: a critical balance. European Respiratory Journal. 2011;38:191-208. DOI: 10.1183/09031936.00146510.
Go to original source... - Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research. 2006;69:562-573. DOI: 10.1016/j.cardiores.2005.12.002.
Go to original source... - Theocharis AD, Skandalis SS, Gialeli C, et al. Extracellular matrix structure. Advanced Drug Delivery Reviews. 2016;97:4-27. DOI: 10.1016/j.addr.2015.11.001.
Go to original source... - Radosinska J, Barancik M, Vrbjar N. Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Medica. 2017;59:241-253. DOI: 10.23736/S0031-0808.17.03321-3.
Go to original source... - Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix metalloproteinase-9: many shades of function in cardiovascular Didease. Physiology. 2013;28:391-403. DOI: 10.1152/physiol.00029.2013.
Go to original source... - Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Canadian Journal of Cardiology. 2006;22(Suppl B):25B30B. DOI: 10.1016/S0828-282X(06)70983-7.
Go to original source... - Azevedo A, Prado AF, Antonio RC, et al. Matrix metalloproteinases are involved in cardiovascular diseases. Basic & Clinical Pharmacology & Toxicology. 2014;115: 301-314. DOI: 10.1111/ bcpt.12282.
Go to original source... - Ahmed SH, Clamk LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of Metalloproteinases. Circulation. 2006;113:2089-2096. DOI: 10.1161/CIRCULATIONAHA.105.573865.
Go to original source... - DeLeon-Pennell KY, Meschiari CA, Jung M, et al. Matrix metalloproteinases in myocardial infarction and heart failure. Progress in Molecular Biology and Translational Science. 2017;147:75-100. DOI: 10.1016/bs.pmbts.2017.02.001.
Go to original source... - Qorri B, Kalaydina RV, Velickovic A, et al. Agonist-biased signaling via matrix metalloproteinase-9 promotes extracellular matrix remodeling. Cells. 2018;7:117. DOI: 10.3390/cells7090117.
Go to original source... - Nascimento RA, Possomato-vieira JS, Bonacio GF, et al. Reductions of Circulating Nitric Oxide are Followed by Hypertension during Pregnancy and Increased Activity of Matrix Metalloproteinases-2 and -9 in Rats. Cells 2019;8
Go to original source... - Kuliczkowski W, Banaszkiewicz M, Mysiak A. Does arterial hypertension affect plasma levels of matrix metalloproteinases and their tissue inhibitors in patients with stable coronary artery disease? A Preliminary Study. Cardiology Research and Practice 2019;2019.
Go to original source... - Ritter AMV, de Faria AP, Barbaro N, et al. Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension. Blood Pressure. 2017;26:122-129. DOI: 10.1080/08037051.2016.1249336.
Go to original source... - Okamoto T, Akaike T, Sawa T, et al. Activation of matrix metalloproteinases by Peroxynitrite-induced Protein S -Glutathiolation via Disulfide S -Oxide Formation * 2001;276:29596-29602. DOI: 10.1074/jbc.M102417200.
Go to original source... - Tothova L, Hodosy J, Mettenburg K, et al. No harmful effect of different Coca-cola beverages after 6 months of intake on rat testes. Food Chem Toxicol. 2013;Dec(62): 343-348. DOI: 10.1016/j. fct.2013.08.073.
Go to original source... - Gyurászová M, Kovalčíková A, Janšáková K, et al. Markers of oxidative stress and antioxidant status in the plasma, urine and saliva of healthy mice. Physiol Res. 2018;67:921-934.
Go to original source... - Bencsik P, Bartekova M, Görbe A, et al. MMP Activity detection in zymograms. methods in molecular biology (Clifton, NJ). 2017;1626:53-70. DOI: 10.1007/978-1-4939-7111-4_6.
Go to original source... - International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478: 103-109. DOI: 10.1038/nature10405.
Go to original source... - Wang S, Li S, Wang B, et al. Matrix metalloproteinase-9 is a predictive factor for systematic hypertension and heart dysfunction in patients with obstructive sleep apnea syndrome. BioMed Research International. 2018;2018. DOI: 10.1155/2018/1569701.
Go to original source... - Yang W, Lu J, Yang L, et al. Association of matrix metalloproteinase-9 gene -1562C/T polymorphism with essential hypertension: A systematic review and meta-analysis article. Iranian Journal of Public Health. 2015;44:1445-1452.
- Tayebjee M, Nadar S, MacFadyen R, et al. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. American Journal of Hypertension. 2004;17: 770-774. DOI: 10.1016/j.amjhyper.2004.06.023.
Go to original source... - Puzserova A, Kopincova J, Bernathova I. Endothelial (dys) function in the experimental model of primary hypertension. Československá Fyziologie. 2010;59.
- Mecocci P, Boccardi V, Cecchetti R, et al. A long journey into aging, brain aging, and Alzheimer's disease following the oxidative stress tracks. Journal of Alzheimer's Disease: JAD. 2018;62:1319-1335. DOI: 10.3233/JAD-170732.
Go to original source... - Nabha L, Garbern JC, Buller CL, et al. Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. Clinical and Experimental Hypertension (New York, NY: 1993). 2005;27:71-82. DOI: 10.1081/ceh-200044267.
Go to original source... - Nakshi S, Kumar DP. Oxidative stress and antioxidants in hypertension-a current review. Current Hypertension Reviews. 2015;11:132-142. DOI: 10.2174/1573402111666150529130922.
Go to original source... - Moldogazieva NT, Mokhosoev IM, Mel'nikova TI et al. Oxidative stress and advanced lipoxidation and glycation end products (ales and ages) in aging and age-related diseases. Oxidative Medicine and Cellular Longevity. 2019;2019: 3085756. DOI: 10.1155/2019/3085756.
Go to original source... - Yavuzer H, Yavuzer S, Cengiz M, et al. Biomarkers of lipid peroxidation related to hypertension in aging. Hypertension Research: Official Journal of the Japanese Society of Hypertension. 2016;39:342-348. DOI: 10.1038/hr.2015.156.
Go to original source... - Cantini C, Kieffer P, Corman B, et al. Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension (Dallas, Tex: 1979). 2001;38: 943-948. DOI: 10.1161/ hy1001.096211.
Go to original source... - De Angelis KL, Oliveira AR, Werner A, et al. Exercise training in aging: hemodynamic, metabolic, and oxidative stress evaluations. Hypertension (Dallas, Tex: 1979). 1997;30(3 Pt 2):767-771. DOI: 10.1161/01.hyp.30.3.767.
Go to original source... - Ahmadiasl N, Soufi FG, Alipour M, et al. Effects of age increment and 36-week exercise training on antioxidant enzymes and apoptosis in rat heart tissue. Journal of Sports Science & Medicine. 2007;6:243-249.
- Hall C. NT-ProBNP: the mechanism behind the marker. Journal of Cardiac Failure. 2005;11(5 Suppl):S81-3. DOI: 10.1016/j. cardfail.2005.04.019.
Go to original source... - Fu M, Zhou J, Qian J, et al. Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction - an experimental study. Lipids Health Dis. 2012;11(106).
Go to original source... - Belo V de A, Parente JM, Tanus-Santos JE, et al. Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension. Biochemical Pharmacology. 2016;118:50-58. DOI: 10.1016/j. bcp.2016.08.012.
Go to original source... - Giannakos E, Vardali E, Bartekova M, et al. Changes in activities of circulating MMP-2 and MMP-9 in patients suffering from heart failure in relation to gender, hypertension and treatment: a cross-sectional study. Physiological Research. 2016;65 Suppl 1:149-152.
Go to original source... - Hopps E, Caimi G. Matrix metalloproteinases as a pharmacological target in cardiovascular diseases. European Review for Medical and Pharmacological Sciences. 2015;19(14):2583-2589. DOI: 9227.

